BFBIO Profit Up 78% in 4QFY25
BF Biosciences (BFBIO) has posted earnings of Rs 127 million, up by 78% year on year (YoY) basis in 4QFY25.
The net earnings stood at Rs 71 million during the same period last year.
The rise in earnings is primarily attributable to higher sales and other income. During 4QFY25, the company’s topline surged by 118%YoY to Rs 1.6 billion, primarily driven by an increase in volume due to newly launched products. PSX, Stock Market, Rollover Week, Investor Sentiment
Similarly, the company posted other income of Rs 48 million versus a loss of Rs 4 million in the same period last year, mainly attributable to higher cash and short-term investments.
BFBIO’s gross margin declined to 34%, down 2pptYoY from 36% in the same period last year. Though we await detailed accounts, our understanding suggests that the company might have sold higher toll-manufactured products, which have lower gross margins.
Having said that, higher depreciation, which relates to Line II, also negatively impacted gross margin. The finance cost declined by 86%YoY due to lower borrowing and interest rates during the period.
During FY25, the company’s earnings grew by 16%YoY, driven primarily by a 60%YoY surge in revenues to Rs5.8bn and a sharp rise in other income to Rs140mn.
